rdf:type |
|
lifeskim:mentions |
|
pubmed:issue |
19
|
pubmed:dateCreated |
1999-12-17
|
pubmed:abstractText |
Novel sulfonamide matrix metalloproteinase inhibitors of general formula (9) were synthesised by a route involving a stereoselective conjugate addition reaction. Enzyme selectivity was found to be dependant on the nature of the sulfonamide substituents. Compounds (9f, 9q) are potent selective collagenase inhibitors with good oral bioavailability.
|
pubmed:language |
eng
|
pubmed:journal |
|
pubmed:citationSubset |
IM
|
pubmed:chemical |
|
pubmed:status |
MEDLINE
|
pubmed:month |
Oct
|
pubmed:issn |
0960-894X
|
pubmed:author |
pubmed-author:BeckettR PRP,
pubmed-author:BellamyC LCL,
pubmed-author:CourtneyP FPF,
pubmed-author:DaviesS JSJ,
pubmed-author:DoddRR,
pubmed-author:DrummondA HAH,
pubmed-author:MartinF MFM,
pubmed-author:PatelS RSR,
pubmed-author:PrattL MLM,
pubmed-author:RickettsM LML,
pubmed-author:ToddR SRS,
pubmed-author:TuffnellA RAR,
pubmed-author:WardJ WJW,
pubmed-author:WhittakerMM
|
pubmed:issnType |
Print
|
pubmed:day |
4
|
pubmed:volume |
9
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
2887-92
|
pubmed:dateRevised |
2003-11-14
|
pubmed:meshHeading |
pubmed-meshheading:10522712-Administration, Oral,
pubmed-meshheading:10522712-Animals,
pubmed-meshheading:10522712-Antineoplastic Agents,
pubmed-meshheading:10522712-Biological Availability,
pubmed-meshheading:10522712-Hydrogen Bonding,
pubmed-meshheading:10522712-Hydroxamic Acids,
pubmed-meshheading:10522712-Matrix Metalloproteinases,
pubmed-meshheading:10522712-Molecular Structure,
pubmed-meshheading:10522712-Protease Inhibitors,
pubmed-meshheading:10522712-Rats,
pubmed-meshheading:10522712-Sulfonamides
|
pubmed:year |
1999
|
pubmed:articleTitle |
The synthesis and biological evaluation of non-peptidic matrix metalloproteinase inhibitors.
|
pubmed:affiliation |
British Biotech Pharmaceuticals Limited, Cowley, Oxford. martinf@britbio.co.uk
|
pubmed:publicationType |
Journal Article
|